Dr. Drapkin earned his medical degree and his doctoral degree in cell biology and genetics through the Tri-Institutional M.D.-Ph.D. Program sponsored by Weill Cornell Medicine, Rockefeller University, and Memorial Sloan Kettering Cancer Center. He completed internal medicine residency training at Massachusetts General Hospital in Boston and received advanced training through a fellowship in hematology and oncology at the Dana-Farber Cancer Institute and Brigham and Women's hospital.
Certified by the American Board of Internal Medicine in medical oncology, Dr. Drapkin joined the UT Southwestern faculty in 2020.
Dr. Drapkin specializes in the care of lung cancer patients, with a focus on small-cell lung cancer. His research focuses on SCLC clinical trials and translational research in SCLC and other aggressive neuroendocrine tumors. His laboratory leverages patient-derived xenograft models to discover new targets and develop new therapies for these deadly diseases. He has published numerous academic articles.
In 2020, he received the University of Texas Lung Cancer SPORE Career Enhancement Program Award and the K08 Mentored Clinical Scientist Research Career Development Award.
- Medical School
- Cornell University Medical College (2010)
- Massachusetts General Hospital (2013), Internal Medicine
- Dana-Farber Cancer Institute (2019), Hematology Oncology